Zydus’ Usnoflast Receives FDA Fast Track for ALS

  Published 1 year ago

Zydus Lifesciences’ Usnoflast (ZYIL1), a novel NLRP3 inhibitor, has received Fast Track Designation from the USFDA for treating ALS. This, alongside Orphan Drug Designation, accelerates development for this serious, unmet medical need.

  • ALS affects ~32K in the US & 75K in India.
  • Usnoflast is in Phase 2(b) trials, following positive Phase 2(a) data.
  • Fast Track offers benefits like priority review & FDA interaction.

You might like these

SBI Urges RBI September Rate Cut

AGI Infra Launches 713‑Unit Luxury Towers

Swati Dalal Appointed Managing Director at Zydus Healthcare

Asian Paints Shares Shift Hands in Major Bulk Deals

EM Funds Shift Away From India

Bank of Baroda Shares Hit 15‑Month High

Japan's Exports Dip Amidst US Tariffs

News that matters the most ⚡